An Expedition of FDA-Approved Anticancer Drugs in 2024: Synthetic Routes, Mechanisms of Action, and Clinical...

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• The U.S. Food and Drug Administration (FDA) plays a crucial role in approving novel anticancer therapies.
• Cancer treatment continually evolves with the introduction of new molecularly targeted agents.

Purpose of the Study:

• To systematically review the 56 anticancer drugs approved by the FDA in 2024.
• To analyze the chemical synthesis, mechanisms of action, and therapeutic indications of these novel agents.
• To provide insights into current trends and future directions in anticancer drug development.

Main Methods:

• Review of FDA-approved anticancer drugs in 2024.
• Categorization into organic small molecules and macromolecular monoclonal antibody conjugates.
• Analysis of chemical synthesis, mechanisms of action, and therapeutic targets.

Main Results:

• FDA approved 56 anticancer drugs: 36 small molecules (kinase inhibitors, antimetabolites, DNA-damaging agents, immune modulators, hormonal antagonists) and 20 macromolecular agents (monoclonal antibodies, antibody-drug conjugates).
• Approved agents target key oncogenic pathways, including critical signaling cascades, nucleotide biosynthesis, and immune checkpoints.
• Examples include Ribociclib, Fluorouracil, Keytruda, and Enhertu, demonstrating diverse therapeutic strategies.

Conclusions:

• The 2024 FDA approvals represent significant progress in cancer therapy, offering diverse mechanisms to combat malignancies.
• These novel agents, including small molecules and antibody conjugates, are crucial for improving patient outcomes.
• Continued analysis of drug structures and targets will guide future anticancer drug development.